Dermapharm Holding SE's market cap is currently ―. The company's EPS TTM is €1.158; its P/E ratio is 27.11; and it has a dividend yield of 3.33%. Dermapharm Holding SE is scheduled to report earnings on May 15, 2024, and the estimated EPS forecast is €―. See an overview of income statement, balance sheet, and cash flow financials.

	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21
Income Statement	-
Total Revenue	€ 263.14M	€ 239.48M	€ 231.64M	€ 272.72M	€ 242.45M
Gross Profit	€ 163.27M	€ 152.12M	€ 146.62M	€ 186.54M	€ 157.00M
EBIT	€ 75.54M	€ 32.38M	€ 59.86M	€ 102.92M	€ 85.73M
EBITDA	€ 89.36M	€ 71.33M	€ 72.43M	€ 122.70M	€ 98.36M
Net Income Common Stockholders	€ 52.45M	€ 14.52M	€ 37.37M	€ 71.65M	€ 61.81M
Balance Sheet	-
Cash, Cash Equivalents and Short-Term Investments	€ 145.88M	€ 98.66M	€ 132.52M	€ 172.06M	€ 131.05M
Total Assets	€ 1.45B	€ 1.42B	€ 1.46B	€ 1.41B	€ 1.34B
Total Debt	€ 0.00	€ 634.24M	€ 0.00	€ 580.30M	€ 0.00
Net Debt	€ -145.88M	€ 535.58M	€ -132.52M	€ 408.24M	€ -131.05M
Total Liabilities	€ 945.88M	€ 961.43M	€ 924.95M	€ 907.13M	€ 914.54M
Stockholders Equity	€ 503.86M	€ 452.99M	€ 534.09M	€ 497.32M	€ 423.20M
Cash Flow	-
Free Cash Flow	€ 81.93M	€ 23.03M	€ 28.89M	€ 88.05M	€ 50.63M
Operating Cash Flow	€ 89.89M	€ 32.82M	€ 39.51M	€ 106.47M	€ 69.85M
Investing Cash Flow	€ -7.75M	€ -9.54M	€ -71.06M	€ -40.53M	€ -39.84M
Financing Cash Flow	€ -32.67M	€ -69.80M	€ -3.03M	€ -23.56M	€ -13.07M

Currency in EUR

Dermapharm Holding SE Earnings and Revenue History

Income Statement >

Dermapharm Holding SE Debt to Assets

Balance Sheet >

Dermapharm Holding SE Cash Flow

Cash Flow >

Dermapharm Holding SE Forecast EPS vs Actual EPS

Earnings >

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing